Categories
Tag: ILMN
Illumina will divest Grail after court backs FTC ruling
Illumina (Nasdaq:ILMN) announced that it plans to divest Grail after a drawn-out legal battle over the $7.1 billion acquisition. In September 2020, Illumina announced an agreement to acquire Grail, a DNA sequencing and array-based tech developer. Grail itself was a startup that initially spun out from the company in 2016….
Stocks Gain; Oil Rises as Conflict Disrupts Red Sea Shipping
Communications Sector Gets a Boost from FAANG 37 minutes ago The communications sector was the best-performing corner of the market Monday, buoyed by big tech firms Meta (META), Netflix (NFLX), and Alphabet (GOOGL). Shares of each were about 3% high Monday afternoon, possibly buoyed by conviction the digital advertising market is…
Illumina Gives Up Fight With Regulators, Will Divest GRAIL
Key Takeways Illumina Inc. decided to end its controversial purchase of GRAIL, and will divest itself of the cancer diagnostic test maker. The deal ran into opposition from regulators in the U.S. and Europe when the DNA sequencing company closed on the GRAIL transaction before receiving approval. Activist investor Carl…
Illumina Announces Decision to Divest GRAIL
SAN DIEGO, Dec. 17, 2023 /PRNewswire/ — Today, Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL. The divestiture will be executed through a third-party sale or capital markets transaction, consistent with the European Commission’s divestiture order, with the goal of finalizing the terms by the end of…
US court strikes down FTC order against Illumina’s purchase of Grail – Business
Business Business US court strikes down FTC order against Illumina’s purchase of Grail Close US court strikes down FTC order against Illumina’s purchase of Grail Follow on Published On: Sat, 16 Dec 2023 …
Illumina: Grail’s Divestment Could Unlock Significant Shareholder Value (NASDAQ:ILMN)
anamejia18/iStock via Getty Images Illumina (NASDAQ:ILMN) has been one of the worst performers in the S&P Health Care Select Fund (XLV), falling 40% in 2023 alone. Illumina’s market cap has fallen from over $75 billion to just $18 billion at the time of this writing, representing an 80% decline from…
Illumina submits Form 10 to the Securities and Exchange Commission
SAN DIEGO, Dec. 11, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) has confidentially submitted a draft registration statement on Form 10 related to its potential divestiture of GRAIL to the U.S. Securities and Exchange Commission, pursuant to an order Illumina received from the European Commission (EC) directing the company to…
12 Best Genomics Stocks To Buy Now
In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there’s one thing that…
Is It Finally Time To Dump Illumina Stock?
Vive la révolution! It’s not just desperate peasants who embrace radical change of the status quo. Innovations by technology companies are often hailed as revolutionary, disrupting the way we live and work. It’s worth remembering that many revolutionaries later became brutal dictators who ruled over their subjects with an iron…
Illumina To Webcast Upcoming Investor Conferences
SAN DIEGO, Nov. 14, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023Fireside Chat at 7:50am Pacific Time (10:50am Eastern Time) Piper Sandler 35th Annual Healthcare Conference on November…
As Illumina stock bounces off a 10-year low, analysts see no quick fix
As shares of Illumina Inc. ILMN, +5.68% trade near 10-year lows, analysts are reining in expectations for the DNA-sequencing company. Illumina shares fell sharply late last week, after the company cut its full-year sales and profit outlook, and continued their tumble on Monday, falling 5.7% and closing at their lowest…
2023-11-13 | NDAQ:ILMN | Press Release
Program aims to address key barriers to genomic sequencing in-country SAN DIEGO, Nov. 13, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health…
Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries
Program aims to address key barriers to genomic sequencing in-country SAN DIEGO, Nov. 13, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health…
Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries -November 13, 2023 at 09:16 am EST
Program aims to address key barriers to genomic sequencing in-country SAN DIEGO, Nov. 13, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health…
Illumina’s stock on track for lowest close in 10 years after cutting guidance
Illumina Inc.’s stock (ILMN) fell 14% Friday to put it on track for its lowest close in 10 years, after the company after the maker of DNA-sequencing technology cut its full-year sales and profit guidance after missing revenue estimates for the third quarter. The stock was last quoted at $91.16….
Illumina shares fall as company cuts forecasts
Shares of Illumina Inc. (ILMN) fell after hours on Thursday after the maker of DNA-sequencing technology cut its full-year sales and profit outlook. The company said it now expected full-year sales to fall 2% to 3%, compared with a forecast in August for around 1% growth, and an adjusted per-share…
5 Best Genome Sequencing Companies
The Genomic And Multi-omic Revolution The first human genome decoding started in 1990 and was first achieved in 2003. It also cost a staggering $3B. Fast forward 20 years, and the cost of genome sequencing has fallen to $600/genome. Or a 5,000,000x reduction in cost! And it could fall to…
Global Precision Medicine Market Size Demonstrates
New York, United States, Nov. 08, 2023 (GLOBE NEWSWIRE) — Precision medicine is a new approach to treating and preventing disease that considers each individual’s genetic, environmental, and lifestyle differences. Giving the proper treatment to the right patient at the right time is the goal of precision medicine. According to…
Illumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors
TSO 500 ctDNA Version 2 delivers faster turnaround time, greater analytical sensitivity, more streamlined workflow, further enabling precision medicine. SAN DIEGO, Nov. 1, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation…
Top 20 Genomics Companies in the World
In this piece, we will take a look at the top 20 genomics companies in the world. If you want to skip our analysis of the genomics industry, then take a look at the Top 5 Genomics Companies in the World. Modern day science has delivered a plethora of advancements…
BioSpace hiring Staff Bioinformatics Scientist – Machine Learning/Classifier Research and Development #2802 (Bay in Raleigh, NC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
Illumina responds to European Commission’s divestiture order
SAN DIEGO , Oct. 13, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ:ILMN), has received an order from the European Commission (EC) directing the company to divest GRAIL. Receipt of the order is an important next step in evaluating divestiture options for GRAIL. Illumina is committed to resolving all issues regarding GRAIL…
Using Genetics to Shield Bees from Varroa Mites
Illumina, Inc. (NASDAQ: ILMN) Genetic technologies could be a gamechanger for Australian beekeepers as they negotiate life with varroa mite and look to future breeding strategies. In September, Australian authorities declared the parasite could not be eradicated. It’s big news for apiarists, who have spent more than 12 months performing…
Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023
Copyright 2023 PR Newswire. All Rights Reserved2023-10-05 SAN DIEGO, Oct. 5, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2023 following the close of market on Thursday, November 9, 2023. On the same day, at 2:00 pm Pacific Time (5:00 pm…
Staff Bioinformatics Scientist – Machine Learning/Classifier Research and Development #2802 (Bay Area) at GRAIL – Menlo Park, CA
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
Investors, Analysts Debate Background of New Illumina CEO
Jacob Thaysen, PhD will become Illumina’s new CEO effective September 25 In announcing Jacob Thaysen, PhD, as its new CEO on Tuesday, Illumina (ILMN) trumpeted his “extensive background and experience” in genomics, life sciences, and technology after more than a decade at Agilent Technologies and five years before that at…
Jacob Thaysen Appointed as Illuminas New CEO A New Era of Innovation and Growth
On September 5, 2023, Illumina, a renowned company specializing in DNA sequencing and array-based technologies, made an exciting announcement. Jacob Thaysen, the current Senior Vice President of Agilent Technologies and President of its Life Sciences and Applied Markets Group, has been appointed as the new Chief Executive Officer of Illumina….
Illumina (ILMN) Names Agilent’s Thaysen CEO After deSouza Left Amid Proxy Fight
Illumina Inc. named Agilent Technologies Inc.’s Jacob Thaysen as its next chief executive officer after former CEO Francis deSouza abruptly left the DNA-sequencing giant amid an investor proxy fight and regulatory opposition to a major acquisition. Thaysen, 48, will become CEO as of Sept. 25, San Diego-based Illumina said Tuesday…
Illumina picks a new CEO amid SEC investigation
Jacob Thaysen, Illumina’s incoming CEO [Image courtesy of Illumina] Illumina (Nasdaq: ILMN) — the DNA sequencing and array-based tech developer — has tapped an Agilent Technologies executive as its new CEO as it seeks to move beyond regulatory scrutiny of its acquisition of Grail. Jacob Thaysen, an Agilent Technologies SVP…
Illumina’s Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer
SAN DIEGO, Sept. 5, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has appointed Jacob Thaysen, Ph.D., senior vice president of Agilent Technologies and president of its Life Sciences and Applied Markets Group, as Chief…
Despite 3-Week Decline, PacBio Stock Doubles in a Year
Pacific Biosciences of California (PacBio; PACB) investors could be forgiven for having questions about the company’s stock after it sank 26% between August 1–25, from $13.34 to $9.92 despite a flurry of developments that included the raising of its revenue forecast for this year and a growing challenge to longtime…
BioSpace hiring Staff Bioinformatics Scientist – Machine Learning/Classifier Research and Development #2802 (Bay in Raleigh, North Carolina, United States
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
Illumina Results Leave Investors, Analysts Anxious
Illumina served up second-quarter results with higher revenues than expected, and played up growing customer shipments for its NovaSeq X. But investors and analysts remain far from reassured about the sequencing giant’s future given a sharply reduced revenue growth forecast for this year, challenges associated with rolling out the sequencing…
Growing Investor Confidence in Illumina’s Potential for Future Growth
In its most recent disclosure with the Securities and Exchange Commission, Connor Clark & Lunn Investment Management Ltd. revealed a 19.3% increase in its stake in Illumina, Inc. (NASDAQ:ILMN) during the first quarter of this year. The firm now owns 133,328 shares of the life sciences company’s stock, representing an…
Illumina expands genomics capabilities in India with opening of Solutions Center
SAN DIEGO, Aug. 17, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of a new office and state-of-the-art Illumina Solutions Center in Bengaluru, India. Senior executives from Illumina and Premas Life Sciences cut the ribbon at Illumina’s India…
AbbVie, Amgen, AstraZeneca, Bayer, and Merck
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced the five founding members of the Alliance for Genomic Discovery (AGD). The…
Could generative AI drive a 17% CAGR for the genomics theme?
Advances in genomics continue to be made as the US, UK and EU all recognise the importance of understanding our genetic material to develop treatments for rare diseases and to be prepared for future pandemics. Generative artificial intelligence (AI) could play a key role in deepening our knowledge of how…
Illumina, Inc. (NASDAQ:ILMN) Q2 2023 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN) Q2 2023 Earnings Call Transcript August 10, 2023 Operator: Good day, ladies and gentlemen, and welcome to the Second Quarter 2023 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be…
Walt Disney, Capri Holdings, Virgin Galactic shares gain, among other movers
By MarketWatch Here are some of the biggest movers in premarket trading Thursday: Stock gainers: Walt Disney Co. shares (DIS) rose 3.7% after the media giant reported a mixed third-quarter and said it will raise prices on almost all of its streaming packages in an aggressive push to boost profit….
Illumina (ILMN) Appoints Steven Barnard as CTO
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Dr. Steven Barnard, Illumina’s Vice President and Head of Global Advanced Science, will serve as its next Chief Technology Officer (CTO), effective immediately. Dr. Alex Aravanis, who held the position of CTO, will be departing…
Dr. Steven Barnard Appointed Chief Technology Officer
SAN DIEGO, Aug. 9, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Dr. Steven Barnard, Illumina’s Vice President and Head of Global Advanced Science, will serve as its next Chief Technology Officer (CTO), effective immediately. Dr. Alex Aravanis, who held…
Senior Bioinformatics and Data Scientist, Translational Bioinformatics job with GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
Staff Bioinformatics Scientist – Machine Learning/Classifier Research and Development (San job with GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
Senior Bioinformatics Data Engineer – Raleigh
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
Illumina’s Positive Earnings Report and the Promising Future of Genetic Analysis
Illumina’s Earnings Report and the Future of Genetic Analysis Illumina (NASDAQ: ILMN), a leading life sciences company, is poised to release its highly anticipated earnings data on August 9th, following the market’s close. This report has generated significant interest from investors and analysts alike, as it provides insights into the…
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research – Guardant Health (NASDAQ:GH), Illumina (NASDAQ:ILMN)
Guardant Health, Inc. GH, a leading precision oncology company, today announced an agreement with Illumina Inc. ILMN, a global leader in DNA sequencing and array-based technologies, that resolves their pending litigation and promotes a shared resolution to advance the companies’ long-term, commercial partnership. The three-year agreement includes a joint request…
Whole-Genome Sequencing for Neonatal testing
The results of the GEMINI study have now been published: jamanetwork.com/journals/jama/article-abstract/2807081?resultClick=1 This is a study that compared the outcomes of genomic sequencing and a targeted neonatal gene-sequencing test in infants. The study found that genomic sequencing had a higher molecular diagnostic yield, meaning that it was more likely to identify…
Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options
SAN DIEGO, July 25, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar’s suite of oncology assays commercially available globally as part of the Illumina portfolio…
OODA Loop – The Future of Blockchain Technology in Synthetic Biology
Synthetic biology is a field that involves the engineering of biological systems to create new organisms or modify existing ones for various applications, such as healthcare, agriculture, and industrial processes. We continue our efforts to understand the risks and opportunities in this exponential industry sector by taking a look at…
20 Countries With Highest Rate Of Down Syndrome
In this detailed article, we’ll talk about 20 countries with the highest rate of down syndrome. You can skip our analysis on progress in corporate healthcare sector on this front and go to 8 Countries With Highest Rate Of Down Syndrome. Each year, around 6,000 babies are born with Down…
The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck – Illumina (NASDAQ:ILMN)
Alliance aims to accelerate therapeutic development and expand the diversity of genomic data through inclusion of more samples from currently underrepresented ancestries SAN DIEGO, July 18, 2023 /PRNewswire/ — Illumina Inc. ILMN, a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and…
Staff Bioinformatics Scientist – Machine Learning/Classifier Research and Development (San Diego) job with GRAIL, Inc.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
Illumina’s Genome Studio Final Report: TOP to FORWARD
Illumina’s Genome Studio Final Report: TOP to FORWARD 0 Hello, I have a final report from Illumina genotyping generated in two ways: Name,Chromosome,Position,GenTrain Score,SNP,ILMN Strand,Customer Strand,NormID And SNP Name,Sample ID,Allele1 – AB,Allele2 – AB,GC Score I also have a file with transformed AB to probably the TOP coding which is…
Baystreet.ca – Illumina Jumps Despite Fine
European Union regulators on Wednesday fined Illumina (NASDAQ: ILMN) a record 432 million euros ($476 million U.S.) for closing its acquisition of cancer test developer Grail without first securing regulatory approval. The fine from the European Commission, the EU’s executive body, amounts to 10% of San Diego-based Illumina’s…
Growing Interest and Confidence: Asset Management One Co. Ltd. Increases Stake in Illumina, Inc.
As of the first quarter of 2023, Asset Management One Co. Ltd. has increased its position in Illumina, Inc. by 2.3%, according to a recent disclosure with the Securities and Exchange Commission (SEC). This development signifies a growing interest in the life sciences company and highlights Asset Management One’s confidence…
Illumina Or Pacific Biosciences? The Upstart Vs. The 800-Pound Gorilla (NASDAQ:ILMN)
gemphotography/iStock via Getty Images Investment Overview One is based in San Diego, the other in Menlo Park, Calif. One has a market cap valuation (at the time of writing) of $29bn, the other $3.1bn. One earned revenues of $4.6bn last year, the other only $128m. One recorded a net loss…
Illumina to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
SAN DIEGO, April 14, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) today announced that it will issue results for the first quarter 2022 following the close of market on Thursday, May 5, 2022. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and…
Forsta AP Fonden Decreases Holdings in Illumina, Inc.: What Does This Mean for the Investment Strategy?
Forsta AP Fonden, a prominent investment firm, has made a significant decrease in its holdings of Illumina, Inc. (NASDAQ:ILMN) during the first quarter of this year. According to the company’s recent Form 13F filing with the Securities and Exchange Commission, Forsta AP Fonden now owns 34,200 shares of Illumina after…
Proficio Capital Partners LLC Acquires Stake in Illumina, Inc. as Company Continues to Thrive in Life Sciences Industry
In a bold and strategic move, Proficio Capital Partners LLC has made its presence known in the industry by acquiring a significant stake in Illumina, Inc. (NASDAQ:ILMN) during the first quarter of this year. The disclosure submitted with the Securities and Exchange Commission revealed that the fund purchased a staggering…
Delta Air Lines, Generac stocks rally, Walgreens and Lordstown Motors shares tumble, and other stocks on the move
By MarketWatch Walgreens stock drops toward a 12-year low after profit miss, slashed outlook; Lordstown stock plunges after bankruptcy filing Here are some of the bigger and more-active movers on Tuesday. Stock gainers Shares of Delta Air Lines Inc. (DAL) ascended more than 3% toward a 14-month high after the…
Staff Bioinformatics Scientist – Machine Learning/Classifier Research and Development (Bay job with GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
Illumina to lay off workers as part of cost cuts amid Icahn fight
Illumina Inc. (ILMN) disclosed Monday that it has begun laying off workers, as the DNA-sequencing company looks to cut costs amid a withering fight with activist investor Carl Icahn. In a filing with the Securities and Exchange Commission, Illumina stated that it began laying off workers on June 21, and…
Senior Bioinformatics Data Engineer #3142 at GRAIL – Menlo Park, CA
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
BioSpace hiring Senior Bioinformatics Data Engineer #3083 in Raleigh, North Carolina, United States
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
GRAIL, Inc. Senior Bioinformatics Data Engineer #3142 in Menlo Park, CA | 848691479
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
Red-Hot Quality Opportunities – GuruFocus.com
The health care sector is currently undergoing a remarkable transformation. The recent focus on genomics has empowered medical professionals to diagnose patients more objectively and adopt proactive measures to maintain the well-being of larger populations. Genomics now encompasses a wide range of applications, including liquid biopsies, genetic testing platforms and…
Lab crunch: British science has nowhere to go
OXFORD, England, June 20 (Reuters) – For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home. Not far away in the rival academic centre…
10x Genomics Stock: The Illumina of Single-Cell Analysis?
The United States is famously the most litigious society in the world. One statistic we’ve come across is that the country spends about $310 billion a year on litigation. One particularly well-known American has been involved in some 3,500 lawsuits, perhaps skewing the statistics a bit. However, our particular interest…
Senior Bioinformatics Engineer (On-Site / Hybrid) – Raleigh
Job Details GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation…
Teachers Retirement System of Kentucky Lowers Stake in Illumina as Company Faces Revenue Decline Amidst Promising Growth Prospects
As of the last reported quarter, Teachers Retirement System of The State of Kentucky has lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.6%. The recent filing with the Securities and Exchange Commission (SEC) indicates that the firm now holds 42,307 shares worth $8,554,000 at the end of…
Alliancebernstein L.P Raises Stake in Illumina Inc. by 145.8% in Q4 and Invests in Emerging Life Sciences Sector
Alliancebernstein L.P., a well-established investment firm, revealed on June 15, 2023 that it had raised its stake in Illumina Inc. (NASDAQ:ILMN) by a staggering 145.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm stated that it now…
Using Next-Generation Sequencing for personalized cancer vaccines
BioNTech, Moderna, and CureVac are the three leading companies working on cancer vaccines based on personalized neoantigens. Even though the average population will know of BioNTech and Moderna for their COVID-19 work, the original business model was heavily centered around cancer therapies, which is what we will cover here. BioNTech…
10 DNA Stocks Billionaires Are Loading Up On
In this article, we discuss 10 DNA stocks that billionaires love. If you want to skip our detailed analysis of the DNA market, head over to 5 DNA Stocks Billionaires Are Loading Up On. Genomics is the study of a complete set of DNA within an organism. The global genomics…
Illumina’s CEO resigns, MacMillan expresses confidence
Illumina Inc. (NASDAQ: ILMN) announced that CEO Francis deSouza has resigned from the DNA sequencing and array-based tech developer. The news, announced yesterday, comes more than a week after Hologic CEO Stephen MacMillan became non-executive board chair. Edwards Lifesciences CFO Scott Ullem filled a second new seat, bringing the board…
2023-06-11 | NDAQ:ILMN | Press Release
SAN DIEGO, June 11, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has accepted the resignation of Francis deSouza as Illumina’s Chief Executive Officer and as a Director, effective Sunday, June 11. Charles Dadswell, Senior…
Illumina CEO Steps Down | Barron’s
Illumina’s CEO stepped down on Sunday amid an ongoing battle over a deal for cancer test developer Grail. Anthony Kwan/Bloomberg Text size Illumina said CEO Francis deSouza resigned from the gene sequencing company as of Sunday as the firm fights regulators over a deal that has also been the target…
Illumina announces CEO transit – GuruFocus.com
SAN DIEGO, June 11, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has accepted the resignation of Francis deSouza as Illumina’s Chief Executive Officer and as a Director, effective Sunday, June 11. Charles Dadswell, Senior…
Illumina announces CEO transition plan
SAN DIEGO, June 11, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has accepted the resignation of Francis deSouza as Illumina’s Chief Executive Officer and as a Director, effective Sunday, June 11. Charles Dadswell, Senior…
Staff Bioinformatics Scientist – Machine Learning/Classifier Research and Development #2802 (San Diego) at GRAIL – San Diego, CA
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
Illumina appeals FTC order to divest cancer test maker Grail
[1/2] A sign at the front entrance to the global headquarters of Illumina is pictured in San Diego, California, U.S., November 28, 2022. REUTERS/Mike Blake/File Photo WASHINGTON, June 5 (Reuters) – Life sciences firm Illumina (ILMN.O) on Monday filed an appeal against a Federal Trade Commission (FTC) order demanding that…
Illumina releases 2022 Corporate Social Responsibility Report
SAN DIEGO, June 5, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its annual Corporate Social Responsibility (CSR) Report, highlighting the company’s commitment to human health, and the progress made by its environmental, social, and governance (ESG) program in 2022….
Illumina’s (ILMN) New AI Tool to Predict Genomics Disease
Illumina, Inc. ILMN recently unveiled new PrimateAI-3D — an artificial intelligence (AI) algorithm which identifies disease-causing genetic mutations in patients. PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software. The National Institutes of Health estimate that the annual production of genomic data is reaching…
Hologic CEO MacMillan to chair Illumina’s board
Hologic CEO Stephen MacMillan Illumina (NASDAQ: ILMN) announced today that its board has elected Hologic CEO Stephan MacMillan to fill a new seat and become its non-executive chair. Edwards Lifesciences CFO Scott Ullem will fill a second new seat — bringing the number of board seats to 11 at the…
Launch of PrimateAI-3D for Accurate Disease Prediction
Illumina, Inc. (NASDAQ: ILMN) launched PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts disease-causing genetic mutations in patients. PrimateAI-3D utilizes deep neural network architectures similar to ChatGPT and AlphaFold, but is trained on genome sequences rather than human language. After applying the algorithm to half a million genomes in the U.K. Biobank…
Illumina’s Board of Directors elects two experienced Independent Directors to Board
Stephen P. MacMillan, Hologic CEO, named non-executive Chair of Illumina’s Board Scott B. Ullem, CFO of Edwards Lifesciences, also named to Board SAN DIEGO, June 2, 2023 /PRNewswire/ —Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced…
Illumina unveils AI software to predict disease-causing genetic mutations in patients
Published findings demonstrate PrimateAI-3D’s ability to improve genetic risk prediction and drug target discovery using primate DNA and advanced artificial intelligence SAN DIEGO, June 1, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the new PrimateAI-3D, an artificial intelligence (AI)…
Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing
Data also shows that current standard-of-care testing for cancer patients falls short in multiple ways SAN DIEGO, May 30, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of the latest data on the impact of comprehensive genomic profiling (CGP)…
Should You Buy Pacific Biosciences Stock Now?
Earlier this month we dissected the ongoing battle between investor activist Carl Icahn and the second-biggest holding in our Nanalyze Disruptive Tech Portfolio – Illumina (ILMN). The latest round just came to an end on May 25 when shareholders approved one of Icahn’s three hand-picked nominees for the gene-sequencing company’s…
Illumina (NASDAQ:ILMN): A Major Victory for Carl Icahn’s Activism
Shareholders of the world’s largest gene sequencing company Illumina, (NASDAQ:ILMN), have proven their disapproval of the board’s past decisions by ousting Chairman John Thompson at the annual shareholder meeting yesterday. Instead, they voted in favor of activist investor Carl Icahn’s nominee, Andrew Teno, marking a first-of-its-kind victory for activism at…
Illumina announces preliminary results of annual meeting
Illumina shareholders re-elect eight of nine Illumina directors SAN DIEGO, May 25, 2023 /PRNewswire/ — Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that based on the preliminary results of its 2023 Annual Meeting, Illumina shareholders have voted to elect eight of nine Illumina…
2023-05-25 | NDAQ:ILMN | Press Release
Illumina shareholders re-elect eight of nine Illumina directors SAN DIEGO, May 25, 2023 /PRNewswire/ — Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that based on the preliminary results of its 2023 Annual Meeting, Illumina shareholders have voted to elect eight of nine Illumina…
Illumina’s Fight With the FTC May Head to the Supreme Court
The biotech company Illumina has become a battleground between big business and big government. In the coming months, courts in the U.S. and Europe will rule whether Illumina (ticker: ILMN) must abandon its $8 billion acquisition of the cancer-testing company Grail, under orders of antitrust authorities. Illumina argues that it’s…
Here’s Why Baron Partners Fund Exited Illumina (ILMN)
Baron Funds, an investment management company, released its “Baron Partners Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. Despite the market volatility, the fund performed well and returned 23.41% in the first quarter, which exceeds the Russell Midcap Growth Index’s 9.14% return and the…
Senior Bioinformatics Engineer (Remote) job with GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…
Carl Icahn Dives Into Activist
Carl Icahn (Trades, Portfolio) is one of the most iconic activist investors or “corporate raiders” that has ever existed. Despite being 87 years old, he is still very active in the market. His latest target is Illumina Inc. (ILMN, Financial), a genomics company which he recently launched a proxy battle…
Illumina Board Chair issues letter to shareholders and urges shareholders to vote the WHITE proxy card FOR all nine of Illumina’s nominees
Board Chair John Thompson issues letter to Illumina shareholders ahead of the company’s Annual Meeting on May 25, 2023 , at 10:00 am Pacific Time ( 1:00 pm Eastern Time ) Illumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina’s director nominees For more…
Carl Icahn and Illumina Square Off Soon. The Stakes Are High.
Carl Icahn, one of Wall Street’s fiercest activists, is taking a big swipe next week, as he attempts to unseat the brash CEO of Illumina, the dominant player in the field of gene sequencing. Illumina ’s (ticker: ILMN) sequencing machines are behind scientific advances already changing science and medicine. The…
Illumina sends letter to shareholders detailing why Illumina’s nominees far outmatch Icahn’s slate in skills and experience
Illumina’s director nominees bring deep commercial, scientific and business experience from leading organizations including Microsoft, Symantec, and Medco-UBC Leading proxy advisory firm ISS has recommended Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein Icahn’s associates bring ZERO relevant experience and ZERO independence Illumina requests shareholders…
Icahn bolstered by another proxy advisor in battle with Illumina
Dive Brief: Illumina shareholders should withhold support for board chair John Thompson and back activist investor Carl Icahn’s nominee Andrew Teno for a seat on the board, proxy advisory firm Institutional Shareholder Services said on May 12. Illumina defended Thompson in a response to the ISS report, saying his deep…
2023-05-15 | NDAQ:IEP | Press Release
Illumina’s director nominees bring deep commercial, scientific and business experience from leading organizations including Microsoft, Symantec, and Medco-UBC Leading proxy advisory firm ISS has recommended Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein Icahn’s associates bring ZERO relevant experience and ZERO independence Illumina requests shareholders…